4E Therapeutics

Development Pipeline

4E Therapeutics is developing a non-opioid approach for the treatment of neuropathic pain by a novel mode of action. The company has demonstrated proof-of-principle with a small molecule MNK inhibitor that has potent analgesic activity in multiple animal pain models. Ongoing optimization efforts aim to generate orally-bioavailable MNK inhibitors with improved tissue-specificity and pharmacokinetic profiles. 4E Therapeutics plans to select their clinical candidate and begin the IND (Investigational New Drug) process in late 2021.

image35